Drugs / JACI-35.054
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04445831 | Jul 2019 → Sep 2023 | Alzheimer disease, brain disorder, cognitive impairment with or without cerebellar ataxia | AC Immune SA | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | AC Immune SA | Results Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine acimmune.com ↗
Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that two different active immunotherapy formulations against the same target can induce a differential antibody response in individuals with early Alzheimer’s disease |
| 2021-05-17 | AC Immune SA | Results AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update acimmune.com ↗
Interim results from the low and second highest dose groups of the Phase 1b/2a trial showed that ACI-35.030 vaccination generated a potent antigen-specific antibody response against pTau in 100% of older patients with early AD with no clinically relevant safety concerns observed to date. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-25 | AC Immune SA | Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine acimmune.com ↗ |
| 2021-05-17 | AC Immune SA | AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update acimmune.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JACI-35.054 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04445831 ↗ |